Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13152656 | 0.91 | MET (0.71) | MET | |
| SCHEMBL3095826 | 0.90 | MET (0.62) | MET | |
| SCHEMBL2348812 | 0.90 | MET (0.62) | MET | |
| SCHEMBL13281981 | 0.90 | MET (0.62) | MET | |
| SCHEMBL3079125 | 0.88 | MET (0.63) | MET | |
| SCHEMBL3092584 | 0.87 | MET (0.61) | MET | |
| SCHEMBL3084139 | 0.86 | MET (0.64) | MET | |
| SCHEMBL3095953 | 0.86 | MET (0.57) | MET | |
| SCHEMBL3088599 | 0.85 | MET (0.76) | MET | |
| SCHEMBL2455862 | 0.85 | MET (0.63) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284300-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-03-15 | — | — | US | claimed |
| US-20150011534-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-01-08 | — | — | US | claimed |
| US-8927540-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2015-01-06 | — | — | US | claimed |
| US-8580781-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-11-12 | — | — | US | claimed |
| US-20130184261-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | claimed |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2164843-A1 | PYRIDAZINONE DERIVATES | Merck Patent GmbH (DE) | 2010-03-24 | — | — | EP | claimed |
| WO-2009006959-A1 | PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2009-01-15 | — | — | WO | claimed |
| EP-2754660-B1 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| US-9403799-B2 | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase | MERCK PATENT GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-9403799-B2 | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase | MERCK PATENT GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-9403799-B2 | Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase | MERCK PATENT GMBH (DE) | 2016-08-02 | — | — | US | disclosed |
| US-9284300-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-03-15 | — | — | US | disclosed |
| US-9284300-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-03-15 | — | — | US | disclosed |
| EP-2164844-A1 | PYRIMIDINYL PYRIDAZINONE DERIVATES | Merck Patent GmbH (DE) | 2010-03-24 | — | — | EP | disclosed |
| EP-2164843-A1 | PYRIDAZINONE DERIVATES | Merck Patent GmbH (DE) | 2010-03-24 | — | — | EP | disclosed |
| WO-2009006959-A1 | PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009006959-A1 | PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007074-A1 | PYRIMIDINYL PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007074-A1 | PYRIMIDINYL PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184261-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885MEN1 164/4885KMT2A 904/4885 |
| US-20150011534-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885MEN1 173/4885KMT2A 1033/4885 |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885MEN1 221/4885KMT2A 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.